Advertisement

Topics

Evolva SA Company Profile

08:55 EDT 26th September 2017 | BioPortfolio

We strive to improve people’s lives by applying our technology and other resources to the discovery and development of new products and processes that benefit the health, well-being and financial economy of patients, consumers and partner companies around the world.

The Company’s primary corporate goal is to build a profitable and sustainable business around its core competencies in compound and pathway discovery and development, and from the commercialisation (by Evolva or its partners) of its product candidates.

We aim to “embed” the results of our technology in products or processes that are partnered with companies and organisations with the expertise and resources to commercialise the products.

Our platform is applicable to a range of industries, including the pharmaceutical, food, chemical and energy sectors. Our main focus is on high value products in the healthcare, nutrition and personal care space.

To achieve this goal the Company intends to employ the following key strategies:

1. Build a balanced portfolio and offset risk

By building a balanced product portfolio, the Company aims to defray risk by increasing the probability of clinical and commercial success and reducing its exposure to the impact of any one product failure. In order to implement this strategy, the Company carries out its own product development programmes, but also plans to partner with third parties in order to defray the cost and risk of clinical development (particularly the cost of late stage clinical trials) and expand marketing power. Although such partnerships may enable the Company to commercialise any approved products without developing its own sales force, the Company may also decide to market approved products on its own in selected indications compatible with its overall resources (e.g., orphan indications, products sold to specialists).

2. Focus on differentiated product candidates that target significant unmet medical needs

We intend to focus on differentiated product candidates that target significant unmet medical needs because they have the potential to provide greater options and choices for the patient or consumer and better pricing potential for the supplier. The Company has chosen to emphasise cardio-renal and infectious disease indications because:

  • together they cause 43% of all deaths in OECD countries, and 51% of all deaths worldwide, and, consequently, are both large markets in which important unmet medical needs remain;
  • compounds created by our technology have similar structural characteristics to natural products, which have an especially strong track record in these sectors;
  • they are especially important segments in emerging pharmaceutical markets such as India and China, and hence are likely to have favourable growth dynamics in the future; and
  • the world’s top 20 pharmaceutical companies are all active in one of these two sectors, providing multiple opportunities to partner.

The Company emphasises small molecule compounds that can be delivered orally. Oral administration is often the most convenient administration route for patients and the most cost-effective for society. In most cases small molecules are also cheaper to manufacture than biologics.

3. Maintain and grow our technology platform

Our proprietary discovery technology platform uses a “disruptive” technological approach to the creation of novel small compounds that differs sharply from the prevailing approaches in the pharmaceutical industry today (i.e., synthetic chemistry and/or protein engineering). As a result, we expect to create compounds with different properties from those discovered by the majority of pharmaceutical companies. We plan to leverage our discovery technology not only to expand its own pipeline, but also to attract third party partners interested in using our technology in their own areas of interest.

4. Maintain and expand discovery and development partnerships

The Company already generates revenues from discovery partnerships with various third parties and plans to maintain and expand its partnerships in both discovery (based primarily on our technology platform) and development (based primarily on our compounds) in the future. The Company sees these partnerships as an important element of its strategy for three main reasons:

  • they help build a balanced portfolio;
  • they provide additional resources and talent; and
  • they could provide us with better understanding of the needs of current and future customers (whether corporations, payors, doctors or patients).

In addition to partnerships in the pharmaceutical sector, we see opportunities to partner in sectors such as bio-defence, pharmaceutical intermediates, industrial chemicals and similar sectors.

Location

Duggingerstrasse 23
Reinach
CH-4153
Switzerland

Contact

Phone: 41 61 485 2000
Fax: 41 61 485 2001
Email: info@evolva.com


News Articles [25 Associated News Articles listed on BioPortfolio]

Evolva Holding SA: Scott Fabro wird neuer Chief Commercial Officer von Evolva

MEDIENMITTEILUNG Scott Fabro wird neuer Chief Commercial Officer von Evolva 12. Juni 2017 - Evolva (SIX: EVE) gibt bekannt, dass Scott Fabro Anfang Juli zu Evolva wechseln und kurz darauf die Nach...

Evolva Holding SA: Neil Goldsmith tritt als CEO und Verwaltungsratsmitglied von Evolva zurück

MEDIENMITTEILUNG Neil Goldsmith tritt als CEO und Verwaltungsratsmitglied von Evolva zurück 6. Juli 2017 - Evolva (SIX: EVE) gibt heute bekannt, dass Neil Goldsmith von seinem Amt als CEO zurücktr.....

Evolva Holding SA: Evolva gibt eine tiefgreifende Restrukturierung im Hinblick auf die nächste Phase der Unternehmensentwicklung bekannt

MEDIENMITTEILUNG Evolva gibt eine tiefgreifende Restrukturierung im Hinblick auf die nächste Phase der Unternehmensentwicklung bekannt 30. August 2017 - Evolva (SIX: EVE), das Inhaltsstoffe der nä.....

Scott Fabro to Join Evolva as Chief Commercial Officer

Evolva announces that Scott Fabro will join Evolva early July and shortly thereafter take over as Chief Commercial Officer, succeeding Luc Gruner. Scott has broad executive experience in various marke...

Restrukturierung beim Biotech-Unternehmen Evolva

Reinach - Bei der in den Bereichen Gesundheits-, Ernährungs- und Wellness-Produkte aktiven Evolva kommt es zu grösseren Veränderungen. In den kommenden Monaten werde eine "umfassende Standortkonso....

Evolva: Simon Waddington zum neuen CEO ernannt

Reinach - Der Chef geht und die Aktie zieht an - so sieht es zum Wochenschluss bei Evolva aus. Der langjährige CEO und Mitgründer Neil Goldsmith tritt von seinem Amt zurück und scheidet auch aus d...

Evolva baut Unternehmen um und streicht Mitarbeiterzahl massiv

(Mit Hintergrund ergänzt) Reinach (awp/sda) - Bei Evolva kommt es zu grösseren Veränderungen. Das in den Bereichen Gesundheits-, Ernährungs- und Wellness-Produkte aktive Unternehmen will in den n...

Evolva erhält Auftrag von US-Behörde zur Weiterentwicklung von Nootkaton

(Ergänzt um weitere Details und Aktienkurs) Zürich (awp) - Evolva hat mit der US-Regierung einen Vertrag über die Entwicklung eines neuen Insektenschutzprodukts auf Basis von Nootkaton abgeschlosse...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [3 Associated Companies listed on BioPortfolio]

Evolva Holding SA

Evolva’s mission is to discover and provide innovative, sustainable ingredients for health, nutrition and wellness. Evolva uses biosynthetic and evolutionary technologies to ...

Evolva SA

We strive to improve people’s lives by applying our technology and other resources to the discovery and development of new products and processes that benefit the health, well-being and financ...

Evolva A/S

We strive to improve people’s lives by applying our technology and other resources to the discovery and development of new products and processes that benefit the health, well-being and financial ec...

More Information about "Evolva SA" on BioPortfolio

We have published hundreds of Evolva SA news stories on BioPortfolio along with dozens of Evolva SA Clinical Trials and PubMed Articles about Evolva SA for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Evolva SA Companies in our database. You can also find out about relevant Evolva SA Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...


Corporate Database Quicklinks



Searches Linking to this Company Record